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phase of sepsis may counteract the cytokine storm. Furthermore,
stabilization of Pellino3 by inhibition of autophagy in the hypoinflammatory
phase of sepsis may improve immunity. In consideration of these two
conflictive sepsis phases, modulation of Pellino3 may provide a new strategy
for the development of a therapy approach in sepsis.
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Background: The multicomponent phagocytic NADPH oxidase produces
reactive oxygen species (ROS) after activation by microorganisms or
inflammatory mediators [1]. In the hypoinflammatory phase of sepsis,
macrophages are alternatively activated by contact with apoptotic cells or
their secretion products. This inhibits NADPH oxidase and leads to
attenuated ROS production [2] and furthermore contributes among others
to a hyporeactive host defense. Due to this immune paralysis, sepsis
patients suffer from recurrent and secondary infections [3]. We focused on
the catalytic subunit of NADPH oxidase, the transmembrane protein NOX2
[4]. We assume that after induction of sepsis the expression of NOX2 is
reduced and hence ROS production is decreased.
Methods: We induced polymicrobial sepsis in mice by cecal ligation and
puncture. The ability of peritoneal macrophages (PMs) to produce ROS was
determined by FACS via hydroethidine assay. NOX2 expression of PMs was
determined by western blot and qPCR. To elucidate the mechanism
causing mRNA destabilization, we performed in vitro experiments using
J774 macrophages. To obtain an alternatively activated phenotype,
macrophages were stimulated with conditioned medium from apoptotic
T cells (CM). By luciferase assays we figured out a 3’UTR-dependent
regulation of NOX2 mRNA stability. Assuming that a protein is involved in
the mRNA degradation, we performed a RNA pulldown with biotinylated
NOX2-3’UTR constructs followed by mass spectrometry. We verified the
role of SYNCRIP by siRNA approach. Additionally, we overexpressed NOX2
in J774 cells and analyzed the ROS production (w/wo CM treatment) by
FACS.
Results: We found an impaired expression of NOX2 at RNA and protein
level along with decreased ROS production after induction of sepsis in mice
as well as stimulating J774 macrophages with CM of apoptotic T cells. This is
due to a time-dependent NOX2 mRNA degradation depending on SYNCRIP,
a RNA-binding protein, which stabilizes NOX2 mRNA through binding to its
3’UTR under normal conditions. In line, knockdown of SYNCRIP also
decreases NOX2 mRNA expression. We assume that a CM-dependent
modification or degradation of SYNCRIP prevents its stabilizing function. As
the overexpression of NOX2 restores ROS production of CM-treated J774
cells, we assume that NOX2 expression is crucial for maintaining NADPH
activity during the hypoinflammatory phase of sepsis.
Conclusion: Our data imply a regulatory impact of SYNCRIP on NOX2
stability during the late phase of sepsis. Therefore, further understanding
of the regulation of NADPH oxidase could lead to the design of a therapy
to reconstitute NADPH oxidase function, finally improving immune
function in sepsis patients.
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Background: The ligand-activated transcription factor, peroxisome-
proliferator-activated receptor gamma (PPARg), has been shown to play an
essential role in immunosuppression during sepsis. PPARg is upregulated in
T cells of septic patients, sensitizing these cells to PPARg-dependent
apoptosis and thus contributing to T-cell depletion [1,2]. In the polymicrobial
cecum ligation and puncture (CLP) sepsis model in mice, both T-cell-specific
gene knockout (Lck-Cre PPARg
fl/fl) and systemic pharmacological PPARg
antagonism by GW9662 improved survival [3]. Because GW9662 was only
effective when applied 3 hours after CLP, we were interested to extend this
time frame. For this reason we characterized the kinetics of SPPARgMs when
administered before or in combination with the agonist thiazolidinedione,
rosiglitazone.
Methods: AP P A R g-dependent transactivation assay was used in HEK293T
cells. It is based on the vector pFA-PPARg-LBD-GAL4-DBD encoding the
hybrid protein PPARg-LBD-GAL4-DBD and the reporter vector pFR-Luc,
carrying a GAL4-responsive element in front of the Firefly luciferase gene.
These two vectors were co-transfected, in combination with a control
vector encoding Renilla luciferase (pRL-CMV) to normalize Firefly luciferase
activity for transfection efficiency. Following transfection, cells were
incubated with the SPPARgMs F-MOC and MCC-555 and the PPARg
antagonist GW9662 for different times (2 to 48 hours) and at increasing
doses (0.01 to 10 μM), with or without rosiglitazone (0.01 to 10 μM).
Transactivation was analyzed using a 96-well plate format.
Results: Rosiglitazone transactivated PPARg in a time-dependent and dose-
dependent manner, the response gradually increasing to a maximum at
48 hours with 10 μM. Low concentrations (0.01 to 0.1 μM) of SPPARgMs
F-MOC and MCC-555 and the PPARg antagonist GW9662 all exerted dose-
independent antagonistic effects at an early incubation time point (2 hours).
From 10 hours onwards, MCC-555 and GW9662, given alone, both exerted
PPARg agonistic effects, MCC-555 in parallel to responses to rosiglitazone,
but GW9662 with characteristics of partial antagonism. F-MOC showed no
dose-dependent effect at any concentration at later time points. Only
GW9662 (1 to 10 μM) was able to inhibit rosiglitazone (0.1 to 1 μM)-induced
PPARg transactivation after 10 hours.
Conclusion: Our kinetic analysis reveals clear differences in the
modulatory characteristics of PPARg inhibitors, with previously unreported
early inhibitory effects and late agonistic or partial agonistic activity. New
SPPARgMs with extended inhibitory activity may prove useful in the
therapy of sepsis.
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